ArticleInternational journal of nanomedicine2015
Anti-hyperglycemic activity of selenium nanoparticles in streptozotocin-induced diabetic rats.
Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed.
- Protective effects of biogenic selenium nanoparticles synthesized by Chlorella Vulgaris against bisphenol a-induced metabolic disturbances in rats.Discover nano · 2026Article
- In vivo and in vitro antidiabetic effects of phlorizin and its green-synthesized phlorizin-selenium nanoparticles in male rats: mechanistic involvements and nanoparticles characterization.Bioresources and bioprocessing · 2026Article
- Allotrope-dependent physicochemical and optical properties of red and grey selenium nanoparticles.RSC advances · 2026Article
- Selenium nanoparticles: Eco-friendly synthesis, biological activities and biomedical applications - A comprehensive review.Materials today. Bio · 2026Review
- Applications of Nano-Selenium in the Poultry Industry: An Overview.Nanomaterials (Basel, Switzerland) · 2026Review
- Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems.Frontiers in medical technology · 2026Review
- Review
- Biochemical and molecular evaluation of resveratrol and selenium nanoparticles in managing type 2 diabetes and its complications.Scientific reports · 2025Article
- Article
- Critical updates on oral insulin drug delivery systems for type 2 diabetes mellitus.Journal of nanobiotechnology · 2025Review
- Nanometerizing Taxifolin Into Selenized Liposomes to Ameliorate Its Hypoglycemic Effect by Optimizing Drug Release and Bioavailability.International journal of nanomedicine · 2025Article
- Neuroprotective Role of Selenium Nanoparticles Against Behavioral, Neurobiochemical and Histological Alterations in Rats Subjected to Chronic Restraint Stress.Molecular neurobiology · 2024Article
- Characterization and biological activity of selenium nanoparticles biosynthesized by Yarrowia lipolytica.Microbial biotechnology · 2024Article
- Selenium Species in Diabetes Mellitus Type 2.Biological trace element research · 2024Review
- MOF-Based Platform for Kidney Diseases: Advances, Challenges, and Prospects.Pharmaceutics · 2024Review
- Recent advances in the therapeutic applications of selenium nanoparticles.Molecular biology reports · 2024Review
- Article
- Nanoselenium attenuates renal ischemia-reperfusion injury in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Assessment of wound healing activity in diabetic mice treated with a novel therapeutic combination of selenium nanoparticles and platelets rich plasma.Scientific reports · 2024Article
- Protective role of selenium and selenium-nanoparticles against multiple stresses in Pangasianodon hypophthalmus.Fish physiology and biochemistry · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study was designed to investigate the anti-hyperglycemic activity of selenium nanoparticles (SeNPs) in streptozotocin-induced diabetic rats. Fifty-five mg/kg of streptozotocin was injected in rats to induce diabetes. Animals either treated with SeNPs alone or with insulin (6 U/kg) showed significantly decreased fasting blood glucose levels after 28 days of treatment. The serum insulin concentration in untreated diabetic animals was also enhanced by SeNPs. The results demonstrated that SeNPs could significantly decrease hepatic and renal function markers, total lipid, total cholesterol, triglyceride and low-density lipoprotein cholesterol levels, and glucose-6-phosphatase activity. At the same time, SeNPs increased malic enzyme, hexokinase and glucose-6-phosphate dehydrogenase activity, liver and kidney glycogen contents, and high-density lipoprotein cholesterol levels. In addition, SeNPs were able to prevent the histological injury in the hepatic and renal tissues of rats. However, insulin injection also exhibited a significant improvement in diabetic animals after 28 days of treatment. This study suggests that SeNPs can alleviate hyperglycemia and hyperlipidemia in streptozotocin-induced diabetic rats, possibly by eliciting insulin-mimetic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.